2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow Relapse Leukemia: new trials by email Literature Review of Relapse Leukemia trials Research Report on Relapse Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia chimeric antigen receptor T cell - Acute Myeloid Leukemia, Relapse Leukemia | Phase 1 / Phase 2 | Completed | Beijing Boren Hospital | 5 | 2021-04-08 | 2024-06-21 |
Leukemia, Myeloid, Acute (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Leukemia (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Hematologic Neoplasms (1) · Histiocytic Disorders, Malignant (1) · Leukemia (1) · Lymphoma (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
Beijing Boren Hospital (1) · Chongqing Precision Biotech Co., Ltd (1)
China (2)
Jia Wei, M.D (1) · Jing Pan, MD/PhD (1)